Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE vs CALCIPOTRIENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
FDA: topical treatment of plaque psoriasis in patients 12 years and older,Off-label: scalp psoriasis, nail psoriasis, parapsoriasis
Plaque psoriasis (FDA-approved),Psoriasis of the scalp (FDA-approved),Chronic plaque psoriasis (off-label),Psoriatic nails (off-label),Ichthyosis (off-label),Vitiligo (off-label)
Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
Calcipotriene: not applicable due to minimal systemic exposure. Betamethasone dipropionate: terminal half-life of betamethasone after topical application is approximately 5-6 hours.
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Calcipotriene: hepatic metabolism via CYP24A1 and other enzymes; betamethasone dipropionate: mainly hepatic metabolism via CYP3A4 to various inactive metabolites.
Calcipotriene undergoes extensive hepatic metabolism via cytochrome P450 enzymes (mainly CYP3A4, CYP2D6, and CYP1A2) to inactive metabolites, which are excreted in feces and urine.
Calcipotriene: negligible systemic absorption; absorbed fraction undergoes hepatic metabolism and is excreted in feces (approx. 70%) and urine (approx. 20%). Betamethasone dipropionate: absorbed dose metabolized in liver, metabolites excreted primarily in urine (60-70%) and feces (20-30%).
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Calcipotriene: >90% bound to plasma proteins (albumin). Betamethasone dipropionate: >90% bound to albumin.
Calcipotriene is approximately 94% bound to plasma proteins, primarily albumin.
Calcipotriene: not clinically relevant due to low systemic absorption. Betamethasone dipropionate: Vd of betamethasone is approximately 1.4 L/kg, indicating wide distribution.
Due to extensive tissue binding and lipophilicity, the apparent volume of distribution (Vd) is estimated to be >5 L/kg, indicating extensive distribution into tissues.
Topical: systemic bioavailability of calcipotriene is <1% of applied dose; betamethasone dipropionate is <10% of applied dose through intact skin, but increases with inflamed skin.
Systemic bioavailability after topical application is less than 1% when applied to normal skin (0.5–1.0%) and up to 5–6% when applied to psoriatic plaques due to increased permeability.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution.
No adjustment required due to minimal systemic absorption.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
No adjustment required due to minimal systemic absorption.
Safety and efficacy in pediatric patients (age <12 years) have not been established. For patients 12–17 years, dosing is same as adult; maximum weekly dose not to exceed 60 g per week.
Children ≥2 years: apply 0.005% cream or ointment once daily, not exceeding 50 g per week. Safety and efficacy in children <2 years not established.
No specific dose adjustment required; however, caution due to potential for increased skin atrophy, impaired renal/hepatic function, and concurrent medications. Use minimal effective amount.
No specific geriatric adjustment; use caution due to increased risk of skin irritation and potential for reduced renal function.
No FDA boxed warning.
None.
May cause hypercalcemia due to calcipotriene absorption, especially when applied to large areas or occluded skin,Risk of hypothalamic-pituitary-adrenal (HPA) axis suppression from betamethasone, particularly with prolonged use, high potency, or large surface area,Local adverse reactions: skin atrophy, striae, telangiectasias, folliculitis, perioral dermatitis, allergic contact dermatitis,Not for use on face, groin, or axillae due to increased systemic absorption and skin atrophy risk,Caution in patients with renal impairment or hepatic impairment due to metabolic and excretory pathways,Do not use with occlusive dressings unless directed,May mask signs of infection and suppress immune response
Hypercalcemia: Avoid exceeding recommended dose; monitor serum calcium, urine calcium, and serum phosphate in patients with renal impairment or when used with other vitamin D products.,Local skin reactions: Irritation, itching, erythema, burning; discontinue if severe.,Photosensitivity: Avoid excessive exposure to sunlight or artificial UV light.,Use on face, groin, or axillae may increase irritation.,Not recommended in patients with known disorders of calcium metabolism.
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any components,Patients with known hypercalcemia or vitamin D toxicity,Active infections of skin (viral, fungal, bacterial) at treatment site,Concurrent use of other vitamin D analogues topically,Severe renal or hepatic impairment (relative)
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcipotriene or any component of the formulation,Use on face, eyes, or mucous membranes
No clinically significant food-drug interactions. However, maintain adequate calcium and vitamin D intake as part of a balanced diet, but avoid excessive calcium supplementation due to potential hypercalcemia risk with extensive use.
No specific food interactions. Maintain adequate calcium and vitamin D intake as per normal dietary recommendations. Avoid high-dose calcium or vitamin D supplements unless prescribed, as additive hypercalcemic risk.
FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause cleft palate, intrauterine growth restriction, and adrenal suppression in animal studies; human risk with topical use is low due to minimal systemic absorption. Avoid large areas or prolonged use in pregnancy. First trimester: theoretical risk but limited data. Second/third trimesters: low risk if used sparingly.
Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be ruled out. First trimester: insufficient data; second and third trimesters: avoid unless clearly needed. Topical application at recommended doses is unlikely to cause harm, but caution advised.
Not known if excreted in human milk. Calcipotriene is likely excreted due to low molecular weight; betamethasone may appear in milk. M/P ratio not available. Use caution; apply smallest amount to smallest area, avoid breast area. Consider benefits vs risks.
Excretion into breast milk unknown. Topical calcipotriene has low systemic absorption; however, avoid application to breast area to prevent infant ingestion. M/P ratio not available. Use with caution in nursing mothers only if clearly needed.
No formal dose adjustment guidelines. Use minimum effective dose for shortest duration. Avoid occlusion, extensive areas, or prolonged treatment. Monitor for local and systemic adverse effects.
No dose adjustment required for topical use as systemic absorption is minimal. However, limit use to small areas to minimize cumulative exposure. No pharmacokinetic studies in pregnancy indicate need for dose change.
Avoid use on face, groin, axillae, or in intertriginous areas due to increased risk of corticosteroid side effects. Apply only to affected plaques; limit total weekly dose to ≤100 g or 60 m L to minimize risk of HPA axis suppression. Discontinue if skin atrophy, telangiectasias, or striae develop. Monitor for hypercalcemia in patients with extensive plaque psoriasis due to calcipotriene absorption. For patients with moderate-to-severe plaque psoriasis, consider sequential or rotational therapy to minimize long-term corticosteroid exposure.
Calcipotriene is a synthetic vitamin D3 analog used primarily for plaque psoriasis. It works by inhibiting keratinocyte proliferation and promoting differentiation. Avoid use on the face, intertriginous areas, and anogenital region due to irritation risk. Maximum weekly dose should not exceed 100 g to avoid hypercalcemia. Use with caution in patients with renal impairment or known hypercalcemia. Combination with topical corticosteroids can enhance efficacy and reduce irritation.
Apply a thin layer to psoriatic plaques once daily for up to 4 weeks as directed.,Do not use on the face, armpits, groin, or areas with skin folds.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not use occlusive dressings (e.g., bandages, wraps) over the treated area.,Inform your doctor if you develop severe skin irritation, signs of skin infection, or if psoriasis worsens.,Do not use more than the prescribed amount or for longer than recommended.
Apply a thin layer to affected areas only, avoiding healthy skin.,Wash hands after application unless treating hands.,Do not use on the face, groin, or skin folds unless specifically directed.,Do not exceed 100 grams per week to avoid side effects.,Avoid excessive sun exposure or tanning beds during treatment.,Inform your doctor if you experience signs of high calcium: nausea, vomiting, constipation, muscle weakness.,Use exactly as prescribed; do not use occlusive dressings unless instructed.,May cause local skin irritation; report severe reactions to your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE vs CALCIPOTRIENE, answered by our medical review team.
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.. CALCIPOTRIENE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE and CALCIPOTRIENE depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is: Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).. The standard adult dose of CALCIPOTRIENE is: Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE and CALCIPOTRIENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is classified as Category C. FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause c. CALCIPOTRIENE is classified as Category C. Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be rule. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.